MDRNA is a biotechnology company focused on the development and commercialization
of therapeutic products based on RNA interference (RNAi). We are building a
broad, flexible and cutting-edge drug discovery platform based on the premise
that no single RNAi technology or delivery approach can overcome the target
specific and indication specific challenges of down regulating protein expression
via a siRNA therapeutic. As a result, we have implemented a multi-faceted, multi-disciplinary
and multi-technological approach to discovering novel and proprietary RNAi-based
therapeutics we are confident will lead to clinical success.
We are employing proven RNAi technologies within a highly adaptable and cell-specific
delivery platform to down-regulate specific protein expression that causes disease.
This approach gives us the flexibility to fully optimize RNAi-based therapies
that target a wide range of diseases based on the unique characteristics of
the cells and organs involved.